JAK2 mutation in the MPDs
Study . | PV . | ET . | MMM . |
|---|---|---|---|
| James et al23 | 40/45 (89) | 9/21 (43) | 3/7 (43) |
| Levine et al24 | 121/164 (74) | 37/115 (32) | 16/46 (35) |
| Baxter et al25 | 71/73 (97) | 29/51 (57) | 8/16 (50) |
| Kralovics et al26 | 83/128 (65) | 21/93 (23) | 13/23 (57) |
| Zhao et al27 | 20/24 (83) | — | — |
| Jones et al28 | 58/72 (81) | 24/59 (41) | 15/35 (43) |
| Total | 393/506 (78) | 120/339 (35) | 55/127 (43) |
Study . | PV . | ET . | MMM . |
|---|---|---|---|
| James et al23 | 40/45 (89) | 9/21 (43) | 3/7 (43) |
| Levine et al24 | 121/164 (74) | 37/115 (32) | 16/46 (35) |
| Baxter et al25 | 71/73 (97) | 29/51 (57) | 8/16 (50) |
| Kralovics et al26 | 83/128 (65) | 21/93 (23) | 13/23 (57) |
| Zhao et al27 | 20/24 (83) | — | — |
| Jones et al28 | 58/72 (81) | 24/59 (41) | 15/35 (43) |
| Total | 393/506 (78) | 120/339 (35) | 55/127 (43) |
Values in the data field represent proportion of patients positive for the JAK2 mutation, with the percentage in parentheses.
— indicates no data.